Generate QR code
Open Access
Subscription Access
Pharmacoeconomic effect of Escherichia coli bacterial lysate in combination therapy for chronic pyelonephritis in the active infl ammatory phase
https://doi.org/10.36485/1561-6274-2026-30-2-82-87
EDN: HPXPZW
Abstract
In recent decades, urinary tract infections (UTIs) have become a leading cause of bacterial infections, posing a threat to human life and health. Chronic pyelonephritis, in particular, is the leading cause of chronic kidney disease.Given the multifactorial pathogenesis of chronic pyelonephritis (CPN), a multidisciplinary approach is crucial in the treatment of this disease. This justifies the need to determine the antimicrobial efficacy of new generations of antibacterial and immunomodulatory drugs, including lyophilized E. coli bacterial lysate, aimed at preventing the progression of CPN and achieving long-term disease remission.
About the Authors
S. A. Oskolkov
Tyumen State Medical University
Russian Federation
Russian Federation
Sergey A. Oskolkov, Prof., MD, PhD, DMedSci, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
S. A. Paketov
Tyumen State Medical University
Russian Federation
Russian Federation
Sergey A. Paketov, Associate Professor, MD, PhD, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
E. A. Sinyayev
Nizhnevartovsk City Polyclinic
Russian Federation
Russian Federation
Evgeniy A. Sinyayev, Associate Professor, Candidate of Medical Sciences, Urologist
628606, Russia, Khanty-Mansi Autonomous Okrug Yugra, Nizhnevartovsk, 9 Neftyanikov Street
V. A. Zhmurov
Tyumen State Medical University
Russian Federation
Russian Federation
Vladimir A. Zhmurov, Prof., MD, PhD, DMediSci, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorsk str., 8
Yu. F. Rashidova
Tyumen State Medical University
Russian Federation
Russian Federation
Rashidova Yulia Fanzarovna, Assistant, Department of Propaedeutics of Internal Diseases
625049, Tyumen, Magnitogorskaya St., 8
References
1. Rice JC, Nicolle LE, Bradley S, Colgan R, Schaeffer A, Hooton TM. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. Clinical Infectious Diseases 2005 ; 40:643–654. doi: 10.1086/427507
2. Wang X, Sun Q, Ding Z, Ji J, Wang J, Kong X, Cai G. Redefining the modular organization of the core Mediator complex. Cell research 2014;24(7):796–808. doi: 10.1038/cr.2014.64
3. Tavichakorntrakool R, Sungkeeree S, Saisud P, Chaiyakhot P, Wongwian A, Pakarasang M, Boonsiri P. Bactericidal efficacy of alcohol solution in community hospital and health centers. Journal of the Medical Association of Thailand=Chotmaihet Thangphaet 2014;97:S44–48. PMID: 24851564
4. Spoorenberg V, Geerlings, SE, Geskus RB, de Reijke TM, Prins JM, Hulscher ME JL. Appropriate antibiotic use for patients with complicated urinary tract infections in 38 Dutch Hospital Departments: a retrospective study of variation and determinants. BMC infectious diseases 2015;15:1–9. PMID: 26553143
5. Brubaker L, Wolfe AJ. The new world of the urinary microbiota in women. American journal of obstetrics and gynecology 2015;213(5);644–649. doi: 10.1016/j.ajog.2015.05.032
6. Barr-Beare E, Saxena V, Hilt EE, Thomas-White K, Schober M, Li B, Schwaderer AL. The interaction between Enterobacteriaceae and calcium oxalate deposits. PloS one 2015; 10(10):e0139575. PMID: 26448465
7. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract—a role beyond infection. Nature Reviews Urology 2015;12(2):81–90. doi: 10.1038/nrurol.2014.361
8. Marien T, Miller NL. Treatment of the infected stone. Urologic Clinics 2015;42(4):459–472. doi: 10.1016/j.ucl.2015.05.009
9. Koval GS, Sinyakova LA, Kosova IV, Borisov VV. Bacterial lysates of Escherichia coli stimulate defensin production by peripheral blood neutrophils in patients with recurrent urinary tract infections. Urologiia 2018;(4):42–47. (In Russ.) doi:10.18565/ urology.2018.4.42-47
10. Migacheva NB. Recurrent lower urinary tract infections: immunological aspects of pathogenesis, treatment, and prevention of relapses. Effective Pharmacotherapy 2022;18 (37):42–54. (In Russ.) doi: 10.33978/2307-3586-2022-18-37-42-54
11. Perepanova TS, Kozlov RS, Rudnov VA, Palagin IS. Immunotherapy with bacterial lysates in chronic pyelonephritis in outpatient practice. Clin Microbiol Antimicrob Chemother 2019;21(3):214222. (In Russ.) doi:10.36488/cmac.2019.3.214-222
12. Alyaev YuG, Glybochko PV, Pushkar DYu, Khodyreva LA. The role of local immunity in the pathogenesis of pyelonephritis and possibilities of its correction. Russ Urol J 2017;5(3):34–41. (Russ.)
13. Rafalskiy VV, Khlynova OV. Non-antibiotic prevention of recurrent urinary tract infections: a review of current guidelines. Ter Arkh 2020;92(4):89–96. (In Russ.) doi:10.26442/00403660.2020.04.000641
Review
For citations:
Oskolkov S.A., Paketov S.A., Sinyayev E.A., Zhmurov V.A., Rashidova Yu.F. Pharmacoeconomic effect of Escherichia coli bacterial lysate in combination therapy for chronic pyelonephritis in the active infl ammatory phase. Nephrology (Saint-Petersburg). 2026;30(2):82-87. (In Russ.) https://doi.org/10.36485/1561-6274-2026-30-2-82-87. EDN: HPXPZW
Views:
49
JATS XML
Email this article 